

July 23, 2025

Cost of Maternal Immunization Delivery

Findings from five low-and middle-income
countries

International Health Economics Association Congress

July 19-23, 2025, Bali, Indonesia

Ranju Baral, PhD, MPH
(On behalf of the study team)



Acknowledgments

Ministries of Health in study countries (Bangladesh, Kenya, Ghana, Mozambique, and Nepal)

Partner organizations and collaborators including KEMRI (Kenya) and BPKIHS (Nepal)

Funding: The Gates Foundation

Outline

Background

Study methods and approach

Results

Summary

Background


- COD is a critical consideration in vaccine introduction decisions as it can be a significant cost borne by countries and a potential barrier to equitable access.
- COD estimates for vaccines given to pregnant women in LMICs are nearly non-existent and delivery strategies and costs may differ from pediatric vaccines.
- PATH conducted studies in **Bangladesh, Ghana, Kenya, Mozambique, and Nepal** in collaboration with local partners.
- The COD estimates generated from this study enhance understanding of the economic feasibility of implementing maternal immunizations.



Costing methods summary

Prospective costing study	A cost projection for the anticipated delivery strategies stakeholders identified for future MI interventions.
Government's perspective	Assumes a government's perspective irrespective of external funding from donors that may be available during introduction.
Incremental costs only	Considers only the additional costs to the existing program in creating a conducive platform for MI interventions.
Activity-based costing	<ul style="list-style-type: none">• Each activity associated with vaccine introduction and delivery are identified and costed individually.• Activities were regrouped into major cost categories (e.g., planning and coordination, communication, training, procurement, distribution, and service delivery).
Time horizon	Costs projections cover a 5-year period and assume national introduction across all districts.
Financial and economic costs	Evaluates both financial (direct financial outlays) and economic costs (including opportunity cost of existing resources and donated goods)

The COD study process



Stakeholder workshop

- **Stakeholder workshop:** In collaboration with the respective Ministry of Health (MOH), we hosted a one-day stakeholder workshop in each country in 2022 or 2023.
- **Purpose:** To discuss feasible delivery strategies for successfully implementing future MI programs within the respective health systems.
- **Participants:** Between 35 and 57 participants including national and select sub-national MOH representatives, academics, researchers, and representatives from various non-governmental organizations.



Kenya



Ghana




Bangladesh

Data collection process

- A **detailed activity map** of implementation activities was developed via interviews with Expanded Program on Immunization (EPI) and maternal, newborn, child health (MNCH) program leads at National and sub-national levels in each country.
 - Included specific calls for any **system-wide changes and adaptations** of the existing health care delivery system needed to create conducive platforms for future MI interventions.
- Recent **experiences with new vaccine introductions and program expectations** informed activity mapping as well as detailed resource needs.
- **Primary data** from representative health administrative units, vaccine stores, and health facilities informed the potential recurring costs at regions/provinces, districts, and facility levels.
- Cost data were collected in local currency units (LCU) and presented in both LCU and USD 2023 units.


MI cost categories and program activities evaluated



Key data inputs and assumptions

Inputs	Bangladesh	Ghana	Kenya	Mozambique	Nepal
Cost of vaccine per dose, (USD), assumed donated	\$3.00 (\$1 and \$5 for sensitivity analyses)				
Syringes and safety boxes per dose	\$0.12	\$0.11	\$0.26	\$0.20	\$0.11
Total procurement add-on charges as a % of product cost (freight, insurance, inspection, handling, taxes)	18%	11%	7.6%	12.9%	35%
Vaccination coverage	90%	88%	50%	50%	75%
Target population (pregnant women) for a given year	4,007,544	1,283,521	1,668,242	1,620,987	515,533

Financial, opportunity, and economic unit cost estimates for MI delivery




References:

Baral et al., 2024. Cost of delivering childhood RSV prevention interventions to the health system in Kenya: a prospective analysis. *BMJ Open*. <https://pubmed.ncbi.nlm.nih.gov/39578037/>

Baral et al., 2025. What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis. *Vaccine*. <https://pubmed.ncbi.nlm.nih.gov/39892111/>

Note: Findings from Nepal and Bangladesh is currently under review and is retracted from this slide.

Comparison with other routine childhood and malaria immunization delivery costs



Note: Any direct comparisons of the cost estimates across studies should be made cautiously because the methods, delivery strategies, settings, and context are different.

This graph plots non-commodity economic cost estimates for MI together with other estimates available for study countries.^{1,2}

Sources

¹Baral et al. 2023 <https://pubmed.ncbi.nlm.nih.gov/36710234/>

²Portnoy et al. 2020 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437655/>

Financial and economic cost drivers for new maternal vaccine delivery by cost share percentage

	FINANCIAL					ECONOMIC				
	Bangladesh	Ghana	Kenya	Mozambique	Nepal	Bangladesh	Ghana	Kenya	Mozambique	Nepal
Procurement										
Program planning and coordination	16%	<1%	7%	11%	15%	68%	<1%	9%	11%	12%
Monitoring and evaluation	21%	1%	4%	1%	7%	10%	<1%	5%	1%	3%
Training	22%	35%	39%	30%	44%	8%	37%	32%	31%	44%
Supervision	1%	4%	9%	8%	3%	1%	4%	13%	9%	2%
Initial sensitization	1%	5%	5%	1%	1%	1%	4%	4%	1%	1%
Demand creation	27%	17%	6%	10%	14%	6%	16%	5%	9%	9%
Service delivery and waste management	<1%	1%	15%	3%	4%	4%	3%	19%	6%	9%
Distribution and storage	5%	17%	6%	27%	7%	1%	15%	8%	23%	17%
Cold chain and other capital purchases	6%	20%	10%	9%	6%	1%	19%	6%	9%	3%

Percentage of total cost

NOTE: "Procurement" is the biggest overall cost driver across countries among the cost categories evaluated in this study, but it is not included in this table so that other key cost drivers can be seen more clearly.

Non-major cost drivers



Major cost drivers

Summary

- The estimated incremental costs of MI delivery (excluding commodity cost) range between **\$1.32 and \$3.42 (financial) and \$2.21 and \$4.12 (economic)** across study countries.
- The economic cost of MI delivery estimates are within the range of routine vaccine delivery cost projections and other recently introduced vaccines.
- These estimates can help countries to evaluate resource needs and can inform other health economic analyses (e.g., cost effectiveness and budget impact).
- Cost data from this study would be strengthened by **validation via a retrospective cost analysis** in a few countries upon MI implementation.

For more
information
contact:

Ranju Baral

rbaral@path.org